← Leaderboards
Jason Sheltzer
Yale University
$5,399,652
Attributed
$6,322,262
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,322,262 · 4
By mechanism
R01$3,485,462 · 2
DP5$2,801,800 · 1
R13$35,000 · 1
Top collaborators
- Ruping Sun4 shared
Most similar at Yale University
Same institution · by research overlap
- Yansheng Liu$3,478,782
- Diane S. Krause$22,809,087
- Nancy Maizels$17,573,272
- Jaakko A Lappalainen$636,150
- Ruping Sun$922,610
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsGenesGeneticTumorMalignant NeoplasmsCancer CellPhenotypeSeriesGrowthMutationTumorigenesisTissuesReportingBiological MarkersCell ProliferationIn VivoKnock-DownClustered Regularly Interspaced Short Palindromic RepeatsExperimental StudyMalignant - DescriptorFitnessLightSide EffectApoptosis
Grant awards (20)
Genomic and functional approaches to characterize Chr1q gains in cancer$520,332
R01 · FY2025 · CA · contact PI
Genomic and functional approaches to characterize Chr1q gains in cancer$490,353
R01 · FY2024 · CA · contact PI
Genomic and functional approaches to characterize Chr1q gains in cancer$301,500
R01 · FY2024 · CA · contact PI
Discovering the mechanisms of-action-mistargeted anti-cancer agents$223,174
R01 · FY2024 · CA · contact PI
Discovering the mechanisms of-action-mistargeted anti-cancer agents$138,745
R01 · FY2024 · CA · contact PI
Genomic and functional approaches to characterize Chr1q gains in cancer$533,035
R01 · FY2023 · CA · contact PI
Discovering the mechanisms of-action-mistargeted anti-cancer agents$230,220
R01 · FY2023 · CA · contact PI
Discovering the mechanisms of-action-mistargeted anti-cancer agents$143,127
R01 · FY2023 · CA · contact PI
Discovering the mechanisms of-action-mistargeted anti-cancer agents$220,368
R01 · FY2022 · CA · contact PI
Discovering the mechanisms of-action-mistargeted anti-cancer agents$146,048
R01 · FY2022 · CA · contact PI
FASEB SRC: The Consequences of Aneuploidy: Honoring the Contributions of Angelika Amon$35,000
R13 · FY2022 · CA · contact PI
Discovering the mechanisms-of-action of mistargeted anti-cancer agents$201,925
R01 · FY2021 · CA · contact PI
Discovering the mechanisms of-action-mistargeted anti-cancer agents$67,355
R01 · FY2021 · CA · contact PI
Identification and characterization of genomic features affecting survival duration in cancer$480,000
DP5 · FY2020 · OD · contact PI
Discovering the mechanisms-of-action of mistargeted anti-cancer agents$269,280
R01 · FY2020 · CA · contact PI
Identification and characterization of genomic features affecting survival duration in cancer$480,000
DP5 · FY2019 · OD · contact PI
Identification and characterization of genomic features affecting survival duration in cancer$480,000
DP5 · FY2018 · OD · contact PI
Identification and characterization of genomic features affecting survival duration in cancer$480,000
DP5 · FY2017 · OD · contact PI
Identification and characterization of genomic features affecting survival duration in cancer$470,800
DP5 · FY2016 · OD · contact PI
Identification and characterization of genomic features affecting survival duration in cancer$411,000
DP5 · FY2015 · OD · contact PI